Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement

Congratulations to our long-time collaboration partners Chia Tai Tianqing Pharmaceutical Group (CTTQ) and Janssen Pharmaceuticals Inc. for reaching an exclusive license agreement.   Under the agreement, CTTQ grants Janssen rights to develop...

WuXi Facility Passes US FDA Inspection for Manufacture of API

We are excited to announce that we have passed a second FDA inspection of our manufacturing facilities.  A manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd (STA)...

WuXi Successfully Hosts 2nd Annual WuXi Global Forum – A Video Summary

Thanks to our esteemed speakers, and great industry support and participation, WuXi Global Forum 2014 was a great success. We created a couple of short videos to capture those special and...

WuXi’s Toxicology Facility in Suzhou Passes OECD GLP Inspection

WuXi's toxicology facility in Suzhou has received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development...

Targos and WuXi Collaborate on Clinical Biomarker Services and Pathology Training in China

Through a strategic biomarker collaboration,  Targos Molecular Pathology GmbH will provide know-how, services, and quality standards to support WuXi's bioanalytical work for pharmaceutical customers.  The collaboration will focus on the validation...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Rejuvenation: The Role of Plasma Proteins in Counterbalancing Aging

The explosion of new biotechnologies and access and understanding of newly mined genomic information has spurred biotech companies and researchers into developing new therapies...